Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 2/20 | 0.50 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 4/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | ATM | Q13315 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.38 |
| ▸ | SOS1 | Q07889 | 1/20 | 0.37 |
| ▸ | CNR2 | P34972 | 2/20 | 0.37 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.37 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.37 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.37 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.37 |
| ▸ | PSMD14 | O00487 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | PPARG | P37231 | 1/20 | 0.36 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30862546 | 1.00 | NOTUM (0.50) | NOTUMGABRA5MAPK1L3MBTL1KDM4E | |
| SCHEMBL2713733 | 0.84 | L3MBTL1 (0.41) | NOTUMMAPK1L3MBTL1KDM4EATM | |
| SCHEMBL2714175 | 0.84 | SCN9A (0.45) | NOTUMGABRA5MAPK1L3MBTL1KDM4E | |
| SCHEMBL439221 | 0.84 | L3MBTL1 (0.54) | GABRA5MAPK1L3MBTL1ALDH1A1CNR1 | |
| SCHEMBL2713825 | 0.84 | NOTUM (0.40) | NOTUMGABRA5MAPK1L3MBTL1KDM4E | |
| SCHEMBL2713784 | 0.83 | L3MBTL1 (0.40) | NOTUMMAPK1L3MBTL1KDM4EATM | |
| SCHEMBL2716361 | 0.83 | NOTUM (0.41) | NOTUMMAPK1L3MBTL1KDM4EATM | |
| SCHEMBL2715307 | 0.83 | SCN9A (0.44) | MAPK1L3MBTL1ATMLMNAPDK2 | |
| SCHEMBL2718304 | 0.81 | NOTUM (0.40) | NOTUMMAPK1L3MBTL1ATMLMNA | |
| SCHEMBL2714070 | 0.81 | GABRA5 (0.48) | NOTUMGABRA5MAPK1L3MBTL1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 51 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250122172-A1 | SUBSTITUTED PYRIDINE AND PYRAZINE COMPOUNDS AS PDE4 INHIBITORS | DART NEUROSCIENCE LLC | 2025-04-17 | — | — | US | disclosed |
| EP-4537901-A2 | COMPOUNDS FOR USE IN TREATING KIDNEY DISORDERS | F. Hoffmann-La Roche AG (CH) | 2025-04-16 | — | — | EP | disclosed |
| EP-3826679-B1 | ABCA1-INDUCING COMPOUNDS FOR USE IN TREATING KIDNEY DISORDERS | HOFFMANN LA ROCHE (CH) | 2024-11-27 | — | — | EP | disclosed |
| US-20230075774-A1 | SUBSTITUTED PYRIDINE AND PYRAZINE COMPOUNDS AS PDE4 INHIBITORS | DART NEUROSCIENCE LLC (US) | 2023-03-09 | — | — | US | disclosed |
| US-11279691-B2 | Substituted pyridine and pyrazine compounds as PDE4 inhibitors | DART NEUROSCIENCE LLC (US) | 2022-03-22 | — | — | US | disclosed |
| US-20210275514-A1 | COMPOUNDS FOR USE IN TREATING KIDNEY DISORDERS | HOFFMANN LA ROCHE (US) | 2021-09-09 | — | — | US | disclosed |
| EP-3826679-A1 | COMPOUNDS FOR USE IN TREATING KIDNEY DISORDERS | F. Hoffmann-La Roche AG (CH) | 2021-06-02 | — | — | EP | disclosed |
| CN-112469442-A | Compounds for treating kidney disorders | 豪夫迈·罗氏有限公司 | 2021-03-09 | — | — | CN | disclosed |
| US-20210015792-A1 | OCTAHYDRO-CYCLOBUTA[1,2-c;3,4-c']DIPYRROL-2-YL | HOFFMANN-LA ROCHE INC. (US) | 2021-01-21 | — | — | US | disclosed |
| US-10849881-B2 | Octahydro-cyclobuta[1,2-c;3,4-c′]dipyrrol-2-yl | HOFFMANN-LA ROCHE INC. (US) | 2020-12-01 | — | — | US | disclosed |
| US-8629166-B2 | 5-cycloalkyl- or 5-heterocyclyl-nicotinamides | HOFFMANN-LA ROCHE INC. (US) | 2014-01-14 | — | — | US | disclosed |
| EP-2630122-A1 | ARYLAMIDE DERIVATIVES AS TTX-S BLOCKERS | RaQualia Pharma Inc (JP) | 2013-08-28 | — | — | EP | disclosed |
| EP-2613785-A1 | HETEROARYLMETHYL AMIDES | F.HOFFMANN-LA ROCHE AG (CH) | 2013-07-17 | — | — | EP | disclosed |
| WO-2013037721-A1 | 5-CYCLOALKYL- OR 5-HETEROCYCLYL-NICOTINAMIDES | F. HOFFMANN-LA ROCHE AG (CH) | 2013-03-21 | — | — | WO | disclosed |
| WO-2013037703-A1 | 3 -PYRIDINE CARBOXYLIC ACID HYDRAZIDES AS HDL-CHOLESTEROL RAISING AGENTS | F. HOFFMANN-LA ROCHE AG (CH) | 2013-03-21 | — | — | WO | disclosed |
| US-20130065876-A1 | 3-PYRIDINE CARBOXYLIC ACID HYDRAZIDES | F. HOFFMANN-LA ROCHE AG (CH) | 2013-03-14 | — | — | US | disclosed |
| US-20130065907-A1 | 5-CYCLOALKYL- OR 5-HETEROCYCLYL-NICOTINAMIDES | F. HOFFMANN-LA ROCHE AG (CH) | 2013-03-14 | — | — | US | disclosed |
| WO-2012053186-A1 | ARYLAMIDE DERIVATIVES AS TTX-S BLOCKERS | RAQUALIA PHARMA INC. (JP) | 2012-04-26 | — | — | WO | disclosed |
| US-20120065212-A1 | HETEROARYLMETHYL AMIDES | F. HOFFMANN-LA ROCHE AG (CH) | 2012-03-15 | — | — | US | disclosed |
| WO-2012032018-A1 | HETEROARYLMETHYL AMIDES | F. HOFFMANN-LA ROCHE AG (CH) | 2012-03-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130065876-A1 | 3-PYRIDINE CARBOXYLIC ACID HYDRAZIDES | HMGCR, HCAR3, HCAR1 | NOTUM 727/4885GABRA5 1585/4885MAPK1 1528/4885 |
| US-20250122172-A1 | SUBSTITUTED PYRIDINE AND PYRAZINE COMPOUNDS AS PDE4 INHIBITORS | PDE4A, PDE4B, PDE4D | NOTUM 4025/4885GABRA5 1000/4885MAPK1 374/4885 |
| US-20130065907-A1 | 5-CYCLOALKYL- OR 5-HETEROCYCLYL-NICOTINAMIDES | NNT, APOB, LDLR | NOTUM 751/4885GABRA5 1544/4885MAPK1 2616/4885 |
| US-20210275514-A1 | COMPOUNDS FOR USE IN TREATING KIDNEY DISORDERS | GLS, ATP6V1B1, PLAAT2 | NOTUM 3652/4885GABRA5 2387/4885MAPK1 3330/4885 |
| US-20210015792-A1 | OCTAHYDRO-CYCLOBUTA[1,2-c;3,4-c']DIPYRROL-2-YL | NPY1R, NPY2R, DECR1 | NOTUM 4057/4885GABRA5 2096/4885MAPK1 3929/4885 |
| US-20230075774-A1 | SUBSTITUTED PYRIDINE AND PYRAZINE COMPOUNDS AS PDE4 INHIBITORS | PDE4A, PDE4B, PDE4D | NOTUM 4025/4885GABRA5 1000/4885MAPK1 374/4885 |
| US-11279691-B2 | Substituted pyridine and pyrazine compounds as PDE4 inhibitors | PDE4A, PDE4B, PDE4D | NOTUM 3994/4885GABRA5 1000/4885MAPK1 372/4885 |
| US-20120065212-A1 | HETEROARYLMETHYL AMIDES | APOB, LDLR, HMGCR | NOTUM 391/4885GABRA5 3402/4885MAPK1 3783/4885 |
| US-10849881-B2 | Octahydro-cyclobuta[1,2-c;3,4-c′]dipyrrol-2-yl | NPY1R, NPY2R, DECR1 | NOTUM 4109/4885GABRA5 2204/4885MAPK1 3913/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.